Your browser is no longer supported. Please, upgrade your browser.
INFI [NASD]
Infinity Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own0.20% Shs Outstand88.66M Perf Week-9.03%
Market Cap228.74M Forward P/E- EPS next Y-0.61 Insider Trans0.00% Shs Float86.79M Perf Month-30.96%
Income-43.00M PEG- EPS next Q-0.14 Inst Own56.90% Short Float6.65% Perf Quarter2.86%
Sales1.90M P/S120.39 EPS this Y18.10% Inst Trans0.06% Short Ratio0.82 Perf Half Y-25.66%
Book/sh0.47 P/B5.36 EPS next Y-10.90% ROA-57.10% Target Price9.25 Perf Year121.05%
Cash/sh1.07 P/C2.35 EPS next 5Y- ROE-304.80% 52W Range1.04 - 5.98 Perf YTD18.87%
Dividend- P/FCF- EPS past 5Y23.70% ROI167.40% 52W High-58.86% Beta1.98
Dividend %- Quick Ratio9.40 Sales past 5Y-56.40% Gross Margin39.70% 52W Low136.52% ATR0.19
Employees23 Current Ratio9.40 Sales Q/Q25.00% Oper. Margin- RSI (14)30.81 Volatility4.55% 6.83%
OptionableYes Debt/Eq0.00 EPS Q/Q22.90% Profit Margin- Rel Volume0.12 Prev Close2.52
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume7.05M Price2.46
Recom1.90 SMA20-13.49% SMA50-23.41% SMA200-22.72% Volume823,915 Change-2.38%
Oct-18-21Initiated H.C. Wainwright Buy $9
Aug-02-21Upgrade JP Morgan Neutral → Overweight $6
Jul-28-21Upgrade Wells Fargo Equal Weight → Overweight $4 → $14
Jul-07-21Resumed B. Riley Securities Buy $7
Mar-18-21Initiated Truist Buy $12
Feb-18-21Initiated Piper Sandler Overweight $7
Feb-05-21Upgrade JP Morgan Underweight → Neutral
Jun-27-19Initiated Oppenheimer Outperform
Jan-04-19Initiated B. Riley FBR Buy $3
Nov-12-18Downgrade Wells Fargo Outperform → Market Perform
Nov-12-18Downgrade JP Morgan Neutral → Underweight
Oct-12-17Upgrade Wells Fargo Market Perform → Outperform
Aug-10-16Reiterated Wedbush Neutral $1.25 → $1
Jun-15-16Downgrade Wells Fargo Outperform → Market Perform
Jun-15-16Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $2
Jun-15-16Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-15-16Downgrade Jefferies Buy → Hold
Jun-14-16Downgrade JP Morgan Overweight → Neutral
Jun-14-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-14-16Downgrade FBR Capital Outperform → Mkt Perform $15 → $2
Oct-26-21 07:35AM  
Oct-18-21 05:22PM  
Oct-01-21 09:27AM  
Sep-13-21 08:35AM  
Sep-07-21 07:35AM  
Sep-02-21 08:35AM  
Aug-23-21 08:32AM  
Aug-04-21 12:00PM  
Aug-03-21 08:00AM  
Aug-02-21 06:07PM  
04:06AM  
Jul-31-21 02:48PM  
Jul-28-21 12:05PM  
Jul-27-21 10:40AM  
08:45AM  
07:31AM  
07:30AM  
05:25AM  
Jul-22-21 03:03PM  
Jul-20-21 08:35AM  
Jun-14-21 08:35AM  
Jun-03-21 04:39AM  
May-28-21 04:17AM  
May-13-21 06:35PM  
04:05PM  
02:30PM  
May-06-21 07:35AM  
May-05-21 08:35AM  
May-03-21 03:01PM  
Apr-27-21 08:35AM  
Apr-13-21 08:59AM  
Mar-29-21 03:22AM  
Mar-19-21 08:47AM  
Mar-16-21 05:35PM  
04:35PM  
04:05PM  
02:30PM  
Mar-10-21 08:35AM  
Mar-09-21 04:01PM  
Mar-02-21 08:35AM  
Feb-20-21 07:40AM  
Feb-18-21 10:02AM  
08:30AM  
Feb-12-21 08:30AM  
08:10AM  
Feb-11-21 04:01PM  
12:38PM  
09:25AM  
09:16AM  
07:15AM  
Feb-10-21 04:05PM  
Jan-20-21 12:00PM  
Jan-15-21 08:35AM  
Jan-11-21 08:53AM  
08:05AM  
Jan-07-21 10:51AM  
08:35AM  
Jan-06-21 09:11AM  
Dec-27-20 02:34AM  
Dec-09-20 12:25PM  
09:10AM  
Dec-07-20 07:35AM  
Dec-02-20 09:47PM  
Nov-17-20 09:22AM  
Nov-12-20 05:53AM  
Nov-09-20 06:35PM  
05:14PM  
04:05PM  
02:30PM  
08:05AM  
Nov-02-20 04:05PM  
Oct-28-20 12:33PM  
Oct-11-20 10:58AM  
Sep-30-20 09:15AM  
Sep-29-20 07:35AM  
Sep-04-20 08:05AM  
Aug-11-20 08:49AM  
08:39AM  
Aug-10-20 03:30PM  
Jul-30-20 06:30PM  
04:05PM  
Jul-23-20 07:35AM  
Jul-08-20 08:22AM  
Jun-10-20 03:46PM  
11:30AM  
08:45AM  
Jun-04-20 08:35AM  
May-12-20 12:48PM  
May-11-20 08:55AM  
07:35AM  
May-04-20 07:35AM  
Apr-28-20 12:33PM  
Apr-20-20 07:59AM  
Apr-10-20 12:00PM  
Apr-07-20 07:35AM  
Apr-02-20 11:30AM  
Mar-26-20 06:07PM  
09:35AM  
Mar-25-20 07:35AM  
Mar-17-20 01:49PM  
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SELBY NORMAN CDirectorMay 14Option Exercise0.925,0004,60015,000May 18 04:32 PM
BVF PARTNERS L P/IL10% OwnerJan 22Sale4.145,848,52024,205,855686,974Jan 26 05:27 PM